May 22, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Breast Cancer

» Advanced search

Paper of the Month - July, 2011

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

Adjuvant docetaxel for high-risk, node-negative breast cancer.

Martín M, Seguí MA, Antón A et al.

Professor Martín’s previous study, BCIRG 001 (Breast Cancer International Research Group 001), clearly demonstrated the benefits of docetaxel as adjuvant chemotherapy when substituted for 5-fluorouracil in the FAC regimen.

Please login or register to continue reading this article

View Archive »


Receptor changes in metachronous breast tumors – our experience of 10 years. - May, 2012
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? - April, 2012
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. - March, 2012
Possible net harms of breast cancer screening: updated modelling of Forrest report. - February, 2012
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. - January, 2012
Sentinel lymph node biopsy in early breast cancer: the experience of the European Institute of Oncology in special clinical scenarios. - December, 2011
Androgen receptor expression and breast cancer survival in postmenopausal women. - November, 2011
Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. - October, 2011
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. - September, 2011
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. - August, 2011
Adjuvant docetaxel for high-risk, node-negative breast cancer. - July, 2011
Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. - June, 2011
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. - May, 2011
Increased risk of severe depression in male partners of women with breast cancer. - April, 2011
Nipple discharge: is its significance as a risk factor for breast cancer fully understood? Observational study including 915 consecutive patients who underwent selective duct excision. - March, 2011
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. - February, 2011
Ipsilateral breast tumour recurrence (IBTR) dynamics in breast conserving treatments with or without radiotherapy. - January, 2011
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. - December, 2010
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. - November, 2010
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. - October, 2010
Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. - September, 2010
Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. - August, 2010
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. - July, 2010
Green tea consumption and breast cancer risk or recurrence: a meta-analysis. - June, 2010
Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. - May, 2010
Factors associated with improved outcome after surgery in metastatic breast cancer patients. - April, 2010
Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. - March, 2010
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. - February, 2010
Oral contraceptives and family history of breast cancer. - January, 2010
Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the Multiethnic Cohort Study. - December, 2009
Breast screening and failure to diagnose breast cancer. - 2009
What is the point: will screening mammography save my life? - 2009
Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the Women’s Environmental Cancer and Radiation Epidemiology Study. - 2009
Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. - 2009
Genes that mediate breast cancer metastasis to the brain. - 2009
Lymph node ratio as an alternative to pN staging in node-positive breast cancer. - 2009
Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. - December, 2009
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. - October, 2009
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. - 2009
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. - 2009
Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. - 2009

READER POLL

What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Continuation of trastuzumab with an alternative cytotoxic agent
An alternative cytotoxic agent alone
A HER1/2 tyrosine kinase inhibitor with or without cytotoxic chemotherapy
Continuation of trastuzumab with a HER1/2 tyrosine inhibitor
Other

WEB LINKS

Original article

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 22, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Breast Cancer » Advanced search